Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Novel technique could offer an improved route to drug discovery and development

A new technique that can analyze how drug molecules bind to proteins in tissue samples could offer an improved route to drug discovery and development.

14 Jul 2022

Hitting rewind on the spread of pancreatic cancer

News-Medical speaks to Linxiang Lan, a staff scientist at The Institute of Cancer Research, about a fundamental discovery that could pave way for new pancreatic cancer treatments.

14 Jul 2022

Diversifying STEM; the Importance of Representation, Equity, and Inclusion

As part of our SLAS Europe 2022 coverage, we speak to Paula Petrone, Associate Research Professor at ISGlobal, about the importance of representation, inclusion, and equity in the STEM fields.

From Society for Laboratory Automation and Screening (SLAS) 13 Jul 2022

Scientists uncover how the innate immune system detects and fights HIV-1

Human immunodeficiency virus 1, more commonly known as HIV-1, is known for its uncanny ability to evade the immune system.

8 Jul 2022

Scientists explore mutations in the SARS-CoV-2 receptor-binding domain

Researchers assessed the different mutations of concern in the SARS-CoV-2 receptor-binding domain.

6 Jul 2022

BICO; Combining Life Sciences Solutions to Further Human Health

As part of our SLAS Europe 2022 coverage, we speak to Héctor Martínez, CTO of BICO, about the technology and services they offer within life sciences research.

From Society for Laboratory Automation and Screening (SLAS) 5 Jul 2022

Combining AI and Zebrafish to Accelerate Drug Discovery

As part of our SLAS Europe 2022 coverage, we speak to Dr. Javier Terriente, Co-founder and Chief of Drug Development at ZeClinics, about how zebrafish could be the future for discovering new therapeutics.

From Society for Laboratory Automation and Screening (SLAS) 1 Jul 2022

Study focuses on how telomerase activity affects the regenerative potential of stem cells in human urine

The Wake Forest Institute for Regenerative Medicine researchers who were the first to identify that stem cells in human urine have potential for tissue regenerative effects, continue their investigation into the power of these cells.

28 Jun 2022

Sanford Burnham Prebys scientist receives NIH grant to continue research on cellular signaling in cancer

Brooke Emerling from Sanford Burnham Prebys has been awarded a new grant from the National Institutes of Health to continue her work on cellular signaling in cancer.

27 Jun 2022

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Rensselaer Polytechnic Institute researchers Gaetano Montelione and Christopher Cioffi will use a five-year, $3.5 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop a low-dose, oral COVID antiviral drug that can be administered at home.

27 Jun 2022

Moffitt researchers reveal a mechanism leading to drug resistance in prostate cancer

Prostate cancer is the most common cancer among men in the United States. Many patients can live long lives due to early detection and treatment with androgen deprivation therapy.

16 Jun 2022

AKT inhibitor miransertib could be a promising new treatment against low-flow vascular malformations

A team of researchers led by Dr. Sandra Castillo and Dr. Mariona Graupera, from the Josep Carreras Leukaemia Research Institute and member of the CIBERONC, have found the AKT inhibitor miransertib could be a new molecular treatment effective against low-flow vascular malformations, a long-awaited milestone.

14 Jun 2022

Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery

Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency.

From Orbit Discovery 14 Jun 2022

Potential applications of bioactive molecules present in fruit peels

A recent study published in Current Issues in Molecular Biology reviewed the potential biological applications of fruit peel extracts.

13 Jun 2022

Metrion Biosciences appoints Dr Benedetta Montagnini as Head of European Business Development

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Benedetta Montagnini as Head of European Business Development. Driven by the uptake of its ion channel discovery services, the appointment follows the recent creation of a Client Services team as Metrion expands its operations and enhanced drug discovery capabilities, internationally.

From Metrion Biosciences Limited 9 Jun 2022

Insilico Medicine plans to launch a fully automated AI-driven robotics lab for drug discovery

Insilico Medicine's end-to-end AI-driven drug discovery platform, Pharma.AI, draws its strength from the quality and quantity of its data. As Insilico scientific advisory board member and Nobel Prize laureate in chemistry Dr. Michael Levitt has said, Insilico's platform capitalizes on the ability of artificial intelligence to take vast amounts of data from many different components and find patterns and make predictions that can point the way to new life-saving medications.

9 Jun 2022

Immune protein could be a target of future treatments for alcohol use disorder

The anxiety that occurs during withdrawal from excessive alcohol use, and contributes to relapse, may be driven in part by the release of an immune protein in the brain, according to a new study from scientists at Scripps Research.

8 Jun 2022

Axol Bioscience introduces CiPA-validated human stem cell-derived ventricular cardiomyocytes to help improve drug discovery

Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation.

From Axol Bioscience Ltd 8 Jun 2022

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.

From Bruker Cellular Analysis 6 Jun 2022

Researchers repurpose a cancer drug for the treatment of neuroinflammatory diseases

The repurposing of FDA-approved drugs for alternative diseases is a faster way of bringing new treatments into the clinic.

3 Jun 2022